Find your next paid study

Institut de Recherches Internationales ServierNCT05786924

~$10 – $7,500

Soft-tissue SarcomaTriple Negative Breast CancerNon-small Cell Lung Cancer+3 more

Phase Ib/IIa Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies

This is a Phase 1b/IIa dose escalation clinical trial determining the recommended phase II dose of SPEDOX-6 in subjects with advanced, therapy-refractory soft-…

University of California, IrvineNCT07064018

~$10 – $6,250

Advanced NRAS-Mutant MelanomaAdvanced NRAS-Mutant Solid TumorsNRAS Mutation+8 more

A First-in-human Study of RLY-8161 for Treatment of Advanced NRAS-Mutant Melanoma and Other Solid Tumors

This is a Phase 1 first-in-human, open-label multicenter study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and prel…

Relay Therapeutics, Inc.NCT07584226

Advanced Malignant Solid NeoplasmRAS MutationLung Cancer+3 more

A Phase Ia/Ib, Open Label, Multi-center, Non-randomized Dose Escalation and Dose Expansion Study of RSC-1255 Alone or in Combination With Hydroxychloroquine in Patients With Advanced Solid Tumor Malignancies

RSC-101 is a Phase 1a/1b clinical trial of RSC-1255 in adult study participants with advanced solid tumor malignancies who are intolerant of existing therapies…

RasCal Therapeutics, Inc.NCT04678648

Solid Tumors (Phase 1)RAS Mutation

A Multi-center, Open-label, Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AN9025 in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations

The goal of this clinical trial is to learn determine if AN9025 is safe and tolerable to treat solid cancer tumors with specific genetic mutations. It will hel…

Adlai Nortye Biopharma Co., Ltd.NCT07252479

PDACPDAC - Pancreatic Ductal AdenocarcinomaNSCLC+5 more

A Phase 1/2, Multicenter, Open-Label Study to Evaluate Safety, Tolerability & Antitumor Activity of TNG462 in Combination With Other Agents in Patients With Pancreatic Cancer With MTAP Loss and Pancreatic or Non-Small Cell Lung Cancer With MTAP Loss & RAS Mutation

TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of or…

Tango Therapeutics, Inc.NCT06922591

RAS MutationNF1 MutationRAF Mutation+1 more

A Phase 1 Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PAS-004, a MEK (1/2) Inhibitor, in Patients With MAPK Pathway-driven Advanced Solid Tumors With a Documented RAS, NF1, or RAF Mutation or Patients Who Have Failed BRAF/MEK Inhibition

The main purpose of this clinical trial is to test PAS-004 in people with advanced solid tumors with rat sarcoma virus (RAS), neurofibromatosis type I (NF1), o…

Pasithea Therapeutics Corp.NCT06299839

Investigation Into the Natural History and Metabolic and Molecular Basis of RASopathies.

The RASopathies are a group of developmental disorders caused by genetic changes in the genes that compose the Ras/mitogen activated protein kinase (MAPK) path…

RAS MutationNeurofibromatosis 1Noonan Syndrome+11 more

Children's Hospital Medical Center, CincinnatiNCT04395495

~$10 – $675

Solid TumorKRAS Mutation-Related Tumors

Phase I Study of NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors

The goal of this clinical trial is to learn about the safety of NEROFE and doxorubicin and how well it works in patients with advanced/unresectable or metastat…